



PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 09/921,143-Conf. #6449 |
| Filing Date | August 3, 2001 |
| First Named Inventor | Timothy A. Coleman |
| Art Unit | 1653 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | PF112P6 |

RECEIVED

JUN 23 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| | FX | US-6,040,157 | 03-21-2000 | Hu et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
|-----------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|----------------------|--------------------------|---|----------------|
| CO | FY | International Search Report, Application No. PCT/US02/26246, mailed May 21, 2003 | |
| | FZ | Statutory Declaration of Kari Alitalo, executed on August 14, 2002, and accompanying Exhibits KA-1 and KA-2 | |
| | GA | Statutory Declaration of Peter Adrian Walton Rogers, executed on August 9, 2002 | |
| | GB | Statutory Declaration of Francis John Ballard, executed on July 16, 2002 | |
| | GC | Statutory Declaration of Kari Alitalo, executed on July 16, 2002, and accompanying Exhibit 1. | |
| | GD | Statutory Declaration of Susan Power, executed on March 22, 2002, and accompanying Appendices I to IV | |
| | GE | Statutory Declaration of Nicholas Kim Hayward, executed on March 26, 2002 | |
| | GF | Statutory Declaration of Stuart A. Aaronson, executed on March 22, 2002, and accompanying Appendices I to III | |
| | GG | Statutory Declaration of Gary Baxter Cox, executed on March 22, 2002, and accompanying Exhibit GBC24 (Statutory Declaration of Peter Adrian Walters, executed on October 26, 2001) | |
| | GH | Statutory Declaration of Frances John Ballard, executed on December 12, 2001, and accompanying Exhibit 1 | |
| | GI | Statutory Declaration of Kari Alitalo, executed on September 24, 2001, and accompanying Exhibits 1 and 2 | |
| | GJ | Statutory Declaration of Peter Adrian Walton Rogers, executed on November 12, 2001, and accompanying Exhibits PAWR1 to PAWR14 | |
| | GK | Statutory Declaration of John Stanley Mattick, executed on December 12, 2000, and accompanying Exhibits JSM1 to JSM4 | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner Signature | | Date Considered | 2/25/04 |
|-----------------------|--|--------------------|---------|



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/921,143-Conf. #6449 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Timothy A. Coleman |
| | | | | Art Unit | 1653 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 2 | Attorney Docket Number | PF112P6 |

RECEIVED

JUN 23 2003

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----|--|--|
| CO | GL | Statutory Declaration of Nicholas Kim Hayward, executed on December 8, 2000, and accompanying Exhibits NKH 1 and 2 | |
| | GM | Statutory Declaration of Jennifer Ruth Gamble, executed on December 12, 2000, and accompany Exhibits JRG 1 to 3 | |
| | GN | Statutory Declaration of Tom Rapoport, executed on December 13, 2000, and accompanying Exhibits TP 1 and 2 | |
| | GO | Statutory Declaration of Stuart A. Aaronson, executed on December 14, 2000, and accompanying CV | |
| | GP | Statutory Declaration of Susan Power, executed on December 13, 2000, and accompanying Appendices 1 to 2 and F161 | |
| | GQ | Statutory Declaration of Gary Baxter Cox, executed on December 13, 2000, and accompanying Exhibits GBC 1 to 23 | |
| | GR | Statutory Declaration of Peter Adrian Walton Rogers, executed on February 16, 2000, and accompanying Exhibit 1 | |
| | GS | Statutory Declaration of Frances John Ballard, executed on February 16, 2000, and accompanying Exhibit 1 | |
| | GT | Statutory Declaration of Kari Alitalo, executed on February 15, 2000, and accompanying Exhibits 1 to 3 | |

TECH CENTER 1600/2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 2/25/04 |
|--------------------|--|-----------------|---------|

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/921,143 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Coleman, T. |
| | | | | Group Art Unit | 1653 |
| | | | | Examiner Name | Unassigned |
| Sheet | 1 | of | 9 | Attorney Docket Number | PF112P6 |



| U.S. PATENT DOCUMENTS | | | | | | |
|--------------------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| Examiner Initials ¹ | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| ✓ | AA | 6,040,157 | | Hu et al. | 03-21-2000 | |
| | AB | 5,935,820 | | Hu et al. | 08-10-1999 | |
| | AC | 5,932,540 | | Hu et al. | 08-03-1999 | |
| | AD | 5,633,147 | | Meissner et al. | 05-27-1999 | |
| | AE | 5,283,354 | | Lemischka | 02-01-1994 | |
| | AF | 5,240,848 | | Keck et al. | 08-31-1993 | |
| | AG | 5,234,908 | | Szabo et al. | 08-10-1993 | |
| | AH | 5,194,596 | | Tischer et al. | 03-16-1993 | |
| | AI | 5,861,301 | | Terman et al. | 01-19-1999 | |
| | AJ | 5,840,693 | | Eriksson et al. | 11-24-1999 | |
| | AK | 5,073,492 | | Chen et al. | 12-17-1991 | |
| | AL | 5,219,739 | | Tischer et al. | 06-15-1993 | |
| | AM | 5,326,695 | | Andersson et al. | 07-05-1994 | |
| | AN | 5,607,918 | | Eriksson et al. | 03-04-1997 | |
| | AO | 5,776,755 | | Alitalo et al. | 07-07-1998 | |
| | AP | 08/510133 | | | 08/1995 | |
| | AQ | 08/585895 | | | 01/1996 | |
| | AR | 08/601132 | | | 02/1996 | |
| | AS | 08/671573 | | | 06/1996 | |
| ✓ | AT | 60/003491 | | | 09/1995 | |
| | AU | 08/554374 | | | 11/1995 | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------------|-----------------------|-------------------------|---------------------|--|--|---|
| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ³ | Number ⁴ | | | |
| Q | AV | WO | 99/46364 | Human Genome Sciences, Inc. | 09-16-1999 | |
| Q | AW | WO | 98/33917 | Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. | 06-08-1998 | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 2/25/04 |
|--------------------|--|-----------------|---------|

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box




PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/921,143 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Coleman, T. |
| | | | | Group Art Unit | 1653 |
| | | | | Examiner Name | Unassigned |
| Sheet | 2 | of | 9 | Attorney Docket Number | PF112P6 |



| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|---|--|---|
| Examiner Initials | Cite No. ¹ | Foreign Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ² | Number ⁴ | | | |
| cc | AX | WO | 98/07832 | Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. Oy | 02-26-1998 | |
| | AY | WO | 96/39515 | Human Genome Sciences, Inc. | 12-12-1996 | |
| | AZ | WO | 96/05856 | Human Genome Sciences, Inc. | 02-29-1996 | |
| | BA | WO | 00/75163 | Human Genome Sciences | 12-14-2000 | |
| | BB | WO | 96/39515 | Human Genome Sciences | 12-12-1996 | |
| | BC | WO | 95/24473 | Human Genome Sciences | 12-14-1995 | |
| | BD | EP | 0 476983 | Merck & Co., Inc. | 03-25-1992 | |
| | BE | WO | 95/24414 | Human Genome Sciences, Inc. | 09-14-1995 | |
| | BF | WO | 95/19985 | Human Genome Sciences, Inc. | 07-27-1995 | |
| | BG | WO | 92/14748 | American Cyanamid Co. | 09-03-1992 | |
| | BH | | 9-403464 | Human Genome Sciences, Inc. | 01-31-1996 | |
| | BI | WO | 99/21590 | Merck & Co. | 05-06-1999 | |
| | BJ | WO | 99/08522 | Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. | 02-25-1999 | |
| | BK | WO | 98/56936 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | 12-17-1998 | |
| | BL | WO | 98/49300 | Collateral Therapeutics | 11-05-1998 | |
| | BM | WO | 98/39035 | The Wistar Institute of Anatomy & Biology | 09-11-1998 | |
| | BN | WO | 98/24811 | Zymogenetics, Inc. | 06-11-1998 | |
| | BO | WO | 98/06844 | Human Genome Sciences, Inc. | 02-19-1998 | |
| | BP | | 710696 | Genentech, Inc. | 09-30-1999 | |
| | BQ | | 0-476983 | Bayne et al. | 03-25-1992 | |
| | BR | | 0-506477 | Bayne et al. | 09-30-1992 | |
| | BS | WO | 97/05250 | University of Helsinki | 02-13-1997 | |
| | BT | WO | 97/09427 | Genentech, Inc. | 03-13-1997 | |

| | | | |
|--------------------|--|-----------------|----------|
| Examiner Signature | | Date Considered | 02/25/04 |
|--------------------|--|-----------------|----------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box




PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | | |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/921,143 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Coleman, T. |
| | | | | Group Art Unit | 1653 |
| | | | | Examiner Name | Unassigned |
| Sheet | 3 | of | 9 | Attorney Docket Number | PF112P6 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|-------------------------|-----------------------------------|--|--|--|
| Examiner Initials | Cite No. ¹ | Foreign Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ³ | Number ⁴ (if known) | | | |
| | BU | WO | 97/17442 | Immunex Corporation | 05-15-1997 | |

| OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS | | | |
|--|--------------------------|---|--|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | |
| CQ | BV | ACHEN <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci. (USA)</i> , 95(2): 548-553 (1998). | |
| | BW | ALDERSON, <i>et al.</i> (1999) Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro. <i>Keystone Symposia, Ocular Cell and Molecular Biology</i> , 202. (Abstract provided) | |
| | BX | ANDERSSON <i>et al.</i> , "Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF," <i>J. Biol. Chem.</i> , 267(16): 11260-11266 (1992). | |
| | BY | ANDERSSON W.F., "Human gene therapy," <i>Science</i> , 256:808-813 (1992). | |
| | BZ | Aprelikova <i>et al.</i> , "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter," <i>Cancer Research</i> , 52:746-748 (1992). | |
| | CA | DIGNAM <i>et al.</i> , "Balbiani ring 3 in <i>chironomus tentans</i> encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar," <i>Gene</i> 88:133-140 (1990). | |
| | CB | FERRARA <i>et al.</i> , "Molecular and biological properties of the vascular endothelial growth factor family of proteins," <i>Endocrine Rev.</i> 13(1): 18-32 (1992). | |
| | CC | FINNERTY <i>et al.</i> , "Molecular cloning of murine FLT and FLT4," <i>Oncogene</i> 8(11): 2293-2298 (1993). | |
| | CD | HELDIN <i>et al.</i> , "Structure of platelet-derived growth factor: implications for functional properties," <i>Growth Factors</i> 8:245-252 (1993). | |
| | CE | EICHMANN <i>et al.</i> , "Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors," <i>Development</i> 125(4): 743-752 (1998). | |
| | CF | PAJUSOLA <i>et al.</i> , "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines," <i>Cancer Research</i> 52:5738-5743 (1992). | |
| | CG | LEUNG <i>et al.</i> , "Vascular endothelial growth factor is a secreted angiogenic mitogen," <i>Science</i> 246:1306-1309 (1989). | |
| ✓ | CH | BREIER <i>et al.</i> , "Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation," <i>Development</i> 114:521-532 (1992). | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner Signature | | Date Considered | 2/25/04 |
|-----------------------|--|--------------------|---------|

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box




PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | | |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/921,143 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Coleman, T. |
| | | | | Group Art Unit | 1653 |
| | | | | Examiner Name | Unassigned |
| Sheet | 4 | of | 9 | Attorney Docket Number | PF112P6 |

| OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS | | | | | |
|--|-----------------------|---|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | 1 ² |
| CE | CI | BELL <i>et al.</i> , "Human epidermal growth factor precursor: cDNA sequence, expression <i>in vitro</i> and gene organization," <i>Nucl. Acids Res.</i> 14(21): 8427-8446 (1986). | | | |
| | CJ | BERSE <i>et al.</i> , Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors," <i>Mol. Biol. Cell.</i> 3:211-220 (1992). | | | |
| | CK | BETSHOLTZ <i>et al.</i> , "cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines," <i>Nature</i> 320:695-699 (1986). | | | |
| | CL | CLAFFEY <i>et al.</i> , "Vascular endothelial growth factor," <i>J. Biol. Chem.</i> 267(23): 16317-16322 (1992). | | | |
| | CM | CORSON <i>et al.</i> , "Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end," <i>Genomics</i> 17:476-484 (1993). | | | |
| | CN | FERRARA <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cellular Biochemistry</i> 47:211-218 (1991). | | | |
| | CO | GEORGE <i>et al.</i> , "Current Methods in Sequence Comparison and Analysis," <i>Macromolecular Seq. and Syn. Selected Meth - Application</i> (Alan R. Liss), pp. 127-149 (1988). | | | |
| | CP | HU <i>et al.</i> , "A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells," <i>FASEB J.</i> , 11:498-504 (1997). | | | |
| | CQ | JOUKOV <i>et al.</i> , "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," <i>EMBO J.</i> 15(2): 290-298 (1996). | | | |
| | CR | JOUKOV <i>et al.</i> , "Proteolytic processing regulates receptor specificity and activity of VEGF-C," <i>EMBO J.</i> 16(13): 3898-3911 (1997). | | | |
| | CS | KAIPAINEN <i>et al.</i> , "The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells," <i>J. Exp. Med.</i> 178:2077-2088 (1993). | | | |
| | CT | KECK <i>et al.</i> , "Vascular permeability factor, an endothelial cell mitogen related to PDGF," <i>Science</i> 246: 1309 (1989). | | | |
| | CU | KINGSLEY, D., "The TGF- β superfamily: new members, new receptors, and new genetic tests of function in different organisms," <i>Genes & Development</i> 8: 133-146 (1994). | | | |
| | CV | KUKK <i>et al.</i> , "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development," <i>Development</i> 122: 3829-37 (1996). | | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 5/25/04 |
|--------------------|--|-----------------|---------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box




PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | | |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/921,143 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Coleman, T. |
| | | | | Group Art Unit | 1653 |
| | | | | Examiner Name | Unassigned |
| Sheet | 5 | of | 9 | Attorney Docket Number | PF112P6 |

| OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| CQ | CW | LEE <i>et al.</i> , "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4," <i>Proc. Natl. Acad. Sci. (USA)</i> , 93:1988-1992 (1996). | |
| | CX | MAGLIONE <i>et al.</i> , "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14," <i>Oncogene</i> 8:925-931 (1993). | |
| | CY | MAGLIONE <i>et al.</i> , "Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9267-9271 (1991). | |
| | CZ | MASSAGUE, J., "The transforming growth factor-beta family," <i>Annu. Rev. Cell Biol.</i> 6:597-641 (1990). | |
| | DA | MATTHEWS <i>et al.</i> , "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to <i>c-kit</i> ," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9026-9030 (1991). | |
| | DB | MILLAUER <i>et al.</i> , "High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis," <i>Cell</i> 72:835-846 (1993). | |
| | DC | MILLAUER <i>et al.</i> , "Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant," <i>Nature</i> 367:576-579 (1994). | |
| | DD | OLTVAI <i>et al.</i> , "Bcl-2 heterodimerizes <i>in vivo</i> with a conserved homolog, bax, that accelerates programmed cell death," <i>Cell</i> 74:609-619 (1993). | |
| | DE | PAULSSON <i>et al.</i> , "The balbani ring 3 gene in <i>chironomus tentans</i> has a diverged repetitive structure split by many introns," <i>J. Mol. Biol.</i> 211:331-349 (1990). | |
| | DF | PAJUSOLA <i>et al.</i> , "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts," <i>Oncogene</i> 8:2931-2937 (1993). | |
| | DG | TISCHER <i>et al.</i> , "Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family," <i>Biochem. & Biophys. Res. Comms.</i> 165(3): 1198-1206 (1989). | |
| | DH | TANAKA <i>et al.</i> , "DNA sequence encoding the amino-terminal region of the human <i>c-src</i> protein: implications of sequence divergence among <i>src</i> -type kinase oncogenes," <i>Mol. Cell Biol.</i> 7(5): 1978-1983 (1987). | |
| | DI | TERMAN <i>et al.</i> , "Identification of a new endothelial cell growth factor receptor tyrosine kinase," <i>Oncogene</i> 6:1677-1683 (1991). | |
| | DJ | TERMAN <i>et al.</i> , "Identification of the <i>kdr</i> tyrosine kinase as a receptor for vascular endothelial cell growth factor," <i>Biochem. Biophys. Res. Commun.</i> 187(3): 1579-1586 (1992). | |

| | | | |
|--------------------|--|-----------------|----------|
| Examiner Signature | | Date Considered | 02/25/04 |
|--------------------|--|-----------------|----------|

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/921,143 |
| | | Filing Date | August 3, 2001 |
| | | First Named Inventor | Coleman, T. |
| | | Group Art Unit | 1653 |
| | | Examiner Name | Unassigned |
| | | Attorney Docket Number | PF112P6 |
| Sheet | 6 | of | 9 |



| OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| CO | DK | TSUJIMOTO <i>et al.</i> , "Analysis of the structure, transcripts, and protein products of <i>bcl-2</i> , the gene involved in human follicular lymphoma," <i>Proc. Natl. Acad. Sci (USA)</i> , 83:5214-5218 (1986). | |
| | DL | TISCHER <i>et al.</i> , "The Human Gene for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> 266(18): 11947-11954 (1991). | |
| | DM | FRIEDMAN, T., "A brief history of gene therapy," <i>Nat. Genetics</i> 2:93-98 (1992). | |
| | DN | WILLIAMS, R.S. "Southwestern internal medicine conference: prospects for gene therapy of ischemic heart disease," <i>Am. J. Med. Sci.</i> 306(2): 129-136 (1993). | |
| | DO | HOCKEL <i>et al.</i> , "Therapeutic angiogenesis," <i>Arch. Surg.</i> 128:423-429 (1993). | |
| | DP | GUZMAN <i>et al.</i> , "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," <i>Circ. Res.</i> 73:1202-1207 (1993). | |
| | DQ | BELLOMO <i>et al.</i> , "Mice Lacking the Vascular Endothelial Growth Factor-B Gene (<i>Vegfb</i>) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ischemia," <i>Circ. Research</i> 89(2): e29-e35 (2000). | |
| | DR | COCKERILL <i>et al.</i> , "Angiogenesis: Models and Modulators" <i>Intl. Rev. Cytology</i> 159:113-160 (1995). | |
| | DS | GAMBLE <i>et al.</i> , "Regulation of In Vitro Capillary Tube Formation by Anti-Integrin Antibodies," <i>J. Cell. Bio.</i> 121(4): 931-943 (1993). | |
| | DT | GOLDSPIEL <i>et al.</i> , "Human Gene Therapy," <i>Clinical Pharmacy</i> 12: 488-505 (1993). | |
| | DU | GRIMMOND <i>et al.</i> , "Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor," <i>Genome Research</i> 6:124-131 (1996). | |
| | DV | HYDE <i>et al.</i> , "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," <i>Nature</i> 362: 250-255 (1993). | |
| | DW | KAY <i>et al.</i> , "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> 262:117-119 (1993). | |
| | DX | KOLODKA <i>et al.</i> , "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer into Rat Hepatocytes in Vivo," <i>Somatic Cell and Molecular Genetics</i> 19(5): 491-497 (1993). | |
| | DY | LITWIN <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 101-129. | |
| | DZ | SHIBUYA <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 519-524 (1990). | |
| | EA | SILINS <i>et al.</i> , "Analysis of the Promoter Region of the Human VEGF-Related Factor Gene," <i>Biochem. Biophys. Res. Comm.</i> 230: 413-418 (1997). | |
| ✓ | EB | STEWART <i>et al.</i> , "Insulin delivery by somatic cell gene therapy," <i>J of Mol. Endocrinology</i> 11: 335-341 (1993). | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 2/25/04 |
|--------------------|--|-----------------|---------|

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/921,143 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Coleman, T. |
| | | | | Group Art Unit | 1653 |
| | | | | Examiner Name | Unassigned |
| Sheet | 7 | of | 9 | Attorney Docket Number | PF112P6 |

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-------------------|-----------------------|---|----------------|
| CE | EC | TOWNSON <i>et al.</i> , "Characterization of the Murine VEGF-Related Factor Gene," <i>Biochem. & Biophys. Res. Comms.</i> 220: 922-928 (1996). | |
| | ED | WALSH <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204: 289-300. | |
| | EF | YOUREY, <i>et al.</i> (2000) Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells. <i>J. Neuroscience</i> , 20: 6781 - 6788. | |
| | EG | YOUREY, <i>et al.</i> (1999) Vascular Endothelial Cell Growth Factor (VEGF)-2 Enhances the Development of Rat Photoreceptor Cells In Vitro. <i>Soc. Cell Biology</i> , 227. (Abstract provided) | |
| | EH | GenBank Accession No. X68203, APRELIKOV <i>et al.</i> , "H.sapiens mRNA for FLT4, class III receptor tyrosine kinase," November 30, 1993. | |
| | EI | GenBank Accession No. M95200, CLAFFEY <i>et al.</i> , "Mouse vascular endothelial growth factor mRNA, complete cds," April 27, 1993. | |
| | EJ | GenBank Accession No. M24160, DIGNAM <i>et al.</i> , "C.tentans 185-kd secretory protein (sp185) mRNA, partial cds, clone pCt185," April 26, 1993. | |
| | EK | GenBank Accession No. M24276, DIGNAM <i>et al.</i> , "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.1," April 26, 1993. | |
| | EL | GenBank Accession No. M24277, DIGNAM <i>et al.</i> , "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.2," April 26, 1993. | |
| | EM | GenBank Accession No. D88689, FINNERTY <i>et al.</i> , "Mus musculus mRNA for flt-1, complete cds," April 14, 2000. | |
| | EN | GenBank Accession No. L07296, FINNERTY <i>et al.</i> , "Mus musculus receptor tyrosine kinase (FLT4) mRNA, complete cds," August 9, 1993. | |
| | EO | GenBank Accession No. X54936, MAGLIONE <i>et al.</i> , "H.sapiens mRNA for placenta growth factor (PIGF)," November 12, 1991. | |
| | EP | GenBank Accession No. S57152, MAGLIONE <i>et al.</i> , "Homo sapiens placenta growth factor 2 (PIGF-2) gene, partial cds," March 5, 2001. | |
| | EQ | GenBank Accession No. X59397, MATTHEWS <i>et al.</i> , "Mouse Flk-1 mRNA for a tyrosine kinase receptor," November 6, 1991. | |
| | ER | GenBank Accession No. X52263, PAULSSON <i>et al.</i> , "C.tentans balbiani ring 3 (BR3) gene," December 18, 1992. | |
| | ES | GenBank Accession No. M63971, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 1," August, 1993. | |
| | ET | GenBank Accession No. M63972, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 2," August 3, 1993. | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 2/25/04 |
|--------------------|--|-----------------|---------|

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box ☐


PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/921,143 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Coleman, T. |
| | | | | Group Art Unit | 1653 |
| | | | | Examiner Name | Unassigned |
| Sheet | 8 | of | 9 | Attorney Docket Number | PF112P6 |

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------------------|-----------------------|---|----------------|
| CQ | EU | GenBank Accession No. M63973, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 3," August 3, 1993. | |
| | EV | GenBank Accession No. M63974, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 4," August 3, 1993. | |
| | EW | GenBank Accession No. M63975, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 5," August 3, 1993. | |
| | EX | GenBank Accession No. M63976, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 6," August 3, 1993. | |
| | EY | GenBank Accession No. M63977, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 7," August 3, 1993. | |
| | EZ | GenBank Accession No. M63978, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 8," August 3, 1993. | |
| | FA | GenBank Accession No. M27281, KECK <i>et al.</i> , "Human vascular permeability factor mRNA, complete cds," August 3, 1993. | |
| | FB | GenBank Accession No. X04571, BELL <i>et al.</i> , "Human mRNA for kidney epidermal growth factor (EGF) precursor," March 21, 1995. | |
| | FC | GenBank Accession No. X63556, CORSON <i>et al.</i> , "H. sapiens mRNA for fibrillin," February 17, 1997. | |
| | FD | GenBank Accession No. L19896, CORSON <i>et al.</i> , "Human fibrillin (FBN1) gene, 5'end including alternative exons A, B, and C, and exon M," November 8, 1994. | |
| | FE | GenBank Accession No. L04947, TERMAN <i>et al.</i> , "Homo sapiens (clones BT3.081.8, BT3.129.5 and BT4.169)," January 6, 1995. | |
| | FF | GenBank Accession No. M16237, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 2," January 13, 1995. | |
| | FG | GenBank Accession No. M16243, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 3," January 13, 1995. | |
| | EH | GenBank Accession No. M16244, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 4, January 13, 1995. | |
| | FI | GenBank Accession No. M16245, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 5," January 13, 1995. | |
| | FJ | GenBank Accession No. K03212, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 6," January 13, 1995. | |
| | FK | GenBank Accession No. K03213, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 7," January 13, 1995. | |
| ✓ | FL | GenBank Accession No. K03214, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 8," January 13, 1995. | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 2/25/04 |
|--------------------|---|-----------------|---------|

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/921,143 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Coleman, T. |
| | | | | Group Art Unit | 1653 |
| | | | | Examiner Name | Unassigned |
| Sheet | 9 | of | 9 | Attorney Docket Number | PF112P6 |




| OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS | | | | |
|--|-----------------------|---|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | T ² |
| CO | FM | GenBank Accession No. K03215, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 9," January 13, 1995. | | |
| | FN | GenBank Accession No. K03216, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 10, January 13, 1995. | | |
| | FO | GenBank Accession No. K03217, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 11," January 13, 1995. | | |
| | FP | GenBank Accession No. K03218, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 12," January 13, 1995. | | |
| | FQ | GenBank Accession No. M13994, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-alpha protein, complete cds," October 31, 1994. | | |
| | FR | GenBank Accession No. M13995, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-3-beta protein, complete cds," October 31, 1994. | | |
| | FS | GenBank Accession No. L22473, OLTVAI <i>et al.</i> , "Human Bax alpha mRNA, complete cds," December 15, 1993. | | |
| | FT | GenBank Accession No. L22474, OLTVAI <i>et al.</i> , "Human Bax beta mRNA, complete cds," December 13, 1993. | | |
| | FU | GenBank Accession No. AJ000185, ACHEN <i>et al.</i> , "Homo Sapiens mRNA for vascular endothelial growth factor-D," February 11, 1998. | | |
| | FV | International Search Report, Application No. PCT/US99/05021. | | |
| | FW | International Search Report, Application No. PCT/US94/05291. | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 2/25/04 |
|--------------------|--|-----------------|---------|

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



RECEIVED

APR 26 2002

Please type a plus sign (+) inside this box.

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office, Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/921,143 |
| | | | | Filing Date | August 3, 2001 |
| | | | | First Named Inventor | Coleman, T. |
| | | | | Group Art Unit | 1653 |
| | | | | Examiner Name | Unassigned |
| Sheet | 1 | of | 1 | Attorney Docket Number | PF112P6 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------------------|--------------------------|----------------------|--------------------------------------|--|--|--|
| Examiner Initials ⁴ | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|-----------------------------------|--------------------------|-------------------------|---------------------|--------------------------------------|--|--|--|
| Examiner Initials ⁴ | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ³ | Number ⁴ | Kind Code ² (if known) | | | |
| CA | FX | EP | 0476983 | A1 | Merck & Co., Inc. | 03-25-1992 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS | | |
|--|--------------------------|---|
| Examiner Initials ⁴ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| CA | FY | International Search Report, Application No. PCT/US01/24658 mailed on Dec. 12, 2001. |
| | | |
| | | |
| | | |
| | | |
| | | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner Signature | | Date Considered | 2/25/04 |
|-----------------------|--|--------------------|---------|

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.